Skip to main content
Fig. 6 | BMC Urology

Fig. 6

From: Development of a high-precision bladder hyperthermic intracavitary chemotherapy device for bladder cancer and pharmacokinetic study

Fig. 6

Kaplan-Meier curves of cumulative incidence rate (CIR) and disease-free survival (DFS) for patients with bladder HIVEC after TUR. a Kaplan-Meier curves of cumulative incidence rate (CIR), and the CIR was 10.9% (14 out of 128 patients) for patients with bladder HIVEC after TUR. b Kaplan-Meier curves of disease-free survival (DFS), and the mean DFS was 39.0±1.2 months (ranging from 8 to 78 months), and the DFS rate was 89.1% during follow-up for patients with bladder HIVEC after TUR

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us